Pulmonary DNA vaccination: Concepts, possibilities and perspectives

Mucosal immunity establishes the first line of defence against pathogens entering the body via mucosal surfaces. Besides eliciting both local and systemic immunity, mucosal vaccination strategies that are non-invasive in nature may increase patient compliance and reduce the need for vaccine application by trained personnel. A relatively new concept is mucosal immunization using DNA vaccines. The advantages of DNA vaccines, such as the opportunity to combine the genetic information of various antigen epitopes and stimulatory cytokines, the enhanced stability and ease of production make this class of vaccines attractive and suitable for mucosal application. In contrast to the area of intranasal vaccination, only a few recent studies have focused on pulmonary immunization and the involvement of the pulmonary immune system in eliciting protective immune responses against inhaled pathogens. This review focuses on DNA vaccine delivery to the lung as a promising approach to prevent pulmonary-associated diseases caused by inhaled pathogens. Attractive immunological features of the lung as a site for immunization, the mechanisms of action of DNA vaccines and the pulmonary application of such vaccines using novel delivery systems will be discussed. We also examine pulmonary diseases prone to prevention or therapeutical intervention by application of DNA vaccines.

• Publication year

  2005

• Venue

  Journal of Controlled Release

• Publication date

  2005-07-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jconrel.2005.05.028PMID 16054263PMCID 7114572
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Coronavirus replication and pathogenesis: Implications for the recent outbreak of severe acute respiratory syndrome (SARS), and the challenge for vaccine development

  2011cited by this paper
• DNA Vaccines

  2006cited by this paper
• Toll-like receptors.

  2005cited by this paper
• Vaccines. Preventing disease and protecting health

  2005cited by this paper
• Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS

  2004cited by this paper
• Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity

  2004influential reference
• Structure

  2004cited by this paper
• Gene-based vaccines and immunotherapeutics

  2004cited by this paper
• A Toll-like Receptor That Prevents Infection by Uropathogenic Bacteria

  2004cited by this paper
• Response of Human Pulmonary Epithelial Cells to Lipopolysaccharide Involves Toll-like Receptor 4 (TLR4)-dependent Signaling Pathways

  2004cited by this paper
• Role ofToll-Like Receptor 4 in Gram-Positive and Gram-Negative Pneumonia inMice

  2004cited by this paper
• The role of Toll-like receptors in combating mycobacteria.

  2004cited by this paper
• Activation of airway epithelial cells by toll-like receptor agonists.

  2004cited by this paper
• Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8

  2004cited by this paper
• Therapeutic Vaccines for Chronic Infections

  2004cited by this paper
• Biology of Toll receptors: lessons from insects and mammals

  2004influential reference
• Toll-like receptors: function and roles in lung disease.

  2004cited by this paper
• Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria.

  2004cited by this paper
• Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formulations following intravenous administration in mice.

  2004cited by this paper
• Airborne transmission of communicable infection--the elusive pathway.

  2004cited by this paper
• Cationic submicron emulsions for pulmonary DNA immunization.

  2004cited by this paper
• A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice

  2004cited by this paper
• Identification of two antigenic epitopes on SARS-CoV spike protein

  2004cited by this paper
• Cationic microparticles are a potent delivery system for a HCV DNA vaccine.

  2004cited by this paper
• Toll-Like Receptor 2 Plays a Role in the Early Inflammatory Response to Murine Pneumococcal Pneumonia but Does Not Contribute to Antibacterial Defense1

  2004cited by this paper
• Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine

  2004cited by this paper
• Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.

  2004cited by this paper
• Toll-like receptors and dendritic cells: for whom the bug tolls.

  2004cited by this paper
• Poly-β amino ester-containing microparticles enhance the activity of nonviral genetic vaccines

  2004cited by this paper
• Immune responses to gene therapy vectors: influence on vector function and effector mechanisms

  2004cited by this paper
• The innate immune response to pneumococcal lung infection: the untold story.

  2004cited by this paper
• Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection.

  2004cited by this paper
• Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

  2004cited by this paper
• Self- and nonself-recognition by C-type lectins on dendritic cells.

  2004cited by this paper
• Toll-like receptor signalling

  2004cited by this paper
• Repeated immunization with plasmid DNA formulated in poly(lactide-co-glycolide) microparticles is well tolerated and stimulates durable T cell responses to the tumor-associated antigen cytochrome P450 1B1.

  2004cited by this paper
• Neutralizing Antibodies in Patients with Severe Acute Respiratory Syndrome-Associated Coronavirus Infection

  2004cited by this paper
• Faculty Opinions recommendation of Response of human pulmonary epithelial cells to lipopolysaccharide involves Toll-like receptor 4 (TLR4)-dependent signaling pathways: evidence for an intracellular compartmentalization of TLR4.

  2004influential reference
• Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis.

  2004cited by this paper
• Generation and Characterization of DNA Vaccines Targeting the Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus

  2004cited by this paper
• Antibody Response of Patients with Severe Acute Respiratory Syndrome (SARS) Targets the Viral Nucleocapsid

  2004cited by this paper
• Engineering synthetic vectors for improved DNA delivery: insights from intracellular pathways.

  2004cited by this paper
• Toll-like receptor 2-deficient mice succumb to Mycobacterium tuberculosis infection.

  2004cited by this paper
• Innate immunity and toll-like receptors: clinical implications of basic science research.

  2004cited by this paper
• Controlling the Toll road to dendritic cell polarization

  2004cited by this paper
• An Exposed Domain in the Severe Acute Respiratory Syndrome Coronavirus Spike Protein Induces Neutralizing Antibodies

  2004cited by this paper
• Single Mucosal, but Not Parenteral, Immunization with Recombinant Adenoviral-Based Vaccine Provides Potent Protection from Pulmonary Tuberculosis1

  2004cited by this paper
• A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.

  2004cited by this paper
• Collectins and their role in lung immunity

  2004cited by this paper
• Modulating vaccine responses with dendritic cells and Toll‐like receptors

  2004cited by this paper
• Vaccines: preventing disease and protecting health.

  2004cited by this paper
• Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA

  2004cited by this paper
• The road to Toll

  2004cited by this paper
• Identification of an Antigenic Determinant on the S2 Domain of the Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Capable of Inducing Neutralizing Antibodies

  2004cited by this paper
• Local and Systemic Immune Responses to Intratracheal Instillation of Antigen and DNA Vaccines in Mice

  2004cited by this paper
• Innate immunity in the lung: how epithelial cells fight against respiratory pathogens

  2004cited by this paper
• Severe Acute Respiratory Syndrome

  2004cited by this paper
• PLGA–PEI nanoparticles for gene delivery to pulmonary epithelium

  2004cited by this paper
• Recognition of single-stranded RNA viruses by Toll-like receptor 7.

  2004cited by this paper
• Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.

  2004cited by this paper
• The Linkage of Innate to Adaptive Immunity via Maturing Dendritic Cells In Vivo Requires CD40 Ligation in Addition to Antigen Presentation and CD80/86 Costimulation

  2004cited by this paper
• A role for niches in the development of a multiplicity of dendritic cell subsets.

  2004cited by this paper
• Toll-like receptors and acquired immunity.

  2004cited by this paper
• Induction of In Vivo Functional Db-Restricted Cytolytic T Cell Activity against a Putative Phosphate Transport Receptor of Mycobacterium tuberculosis1

  2004influential reference
• An overview of current delivery systems in cancer gene therapy.

  2004cited by this paper
• Synthetic Peptide Studies on the Severe Acute Respiratory Syndrome (SARS) Coronavirus Spike Glycoprotein: Perspective for SARS Vaccine Development

  2004cited by this paper
• Defensins: antimicrobial peptides of innate immunity

  2003cited by this paper
• Taking our breath away: dendritic cells in the pathogenesis of asthma

  2003cited by this paper
• Structure, lymphatic vascularization and lymphocyte migration in mucosa‐associated lymphoid tissue

  2003cited by this paper
• Respiratory Syncytial Virus Up-regulates TLR4 and Sensitizes Airway Epithelial Cells to Endotoxin*

  2003cited by this paper
• Pulmonary gene delivery by chitosan-pDNA complex powder prepared by a supercritical carbon dioxide process.

  2003cited by this paper
• The Effect of CTAB Concentration in Cationic PLG Microparticles on DNA Adsorption and in Vivo Performance

  2003cited by this paper
• Gene Vaccines

  2003cited by this paper
• Severe acute respiratory syndrome (SARS): infection control

  2003cited by this paper
• Toll-like receptor 4 plays no role in susceptibility of mice to Mycobacterium tuberculosis infection.

  2003cited by this paper
• Non-viral gene therapy: polycation-mediated DNA delivery

  2003cited by this paper
• Reverse Vaccinology and Genomics

  2003cited by this paper
• Coronavirus as a possible cause of severe acute respiratory syndrome

  2003cited by this paper
• Severe acute respiratory syndrome (SARS): breath-taking progress.

  2003cited by this paper
• Activation of Toll-Like Receptor 2 on Human Tracheobronchial Epithelial Cells Induces the Antimicrobial Peptide Human β Defensin-2 1

  2003cited by this paper
• Recent progress in the development and testing of vaccines against human tuberculosis.

  2003cited by this paper
• Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice.

  2003cited by this paper
• The Severe Acute Respiratory Syndrome

  2003cited by this paper
• Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection

  2003cited by this paper
• DC-SIGN Is the Major Mycobacterium tuberculosis Receptor on Human Dendritic Cells

  2003cited by this paper
• DNA vaccines: a review

  2003cited by this paper
• Hong Kong bears brunt of latest outbreak

  2003cited by this paper
• The Toll‐like receptor 7 (TLR7)‐specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily

  2003cited by this paper
• DC-SIGN: escape mechanism for pathogens

  2003cited by this paper
• Airway dendritic cells: Co‐ordinators of immunological homeostasis and immunity in the respiratory tract

  2003cited by this paper
• Generation of Toxoplasma gondii GRA1 protein and DNA vaccine loaded chitosan particles: preparation, characterization, and preliminary in vivo studies.

  2003cited by this paper
• Some interfaces of dendritic cell biology

  2003cited by this paper
• The Genome Sequence of the SARS-Associated Coronavirus

  2003cited by this paper
• Poly (D, L-lactide-co-glycolide)/DNA microspheres to facilitate prolonged transgene expression in airway epithelium in vitro, ex vivo and in vivo

  2003cited by this paper
• Two years into reverse vaccinology.

  2003cited by this paper
• Enhanced Mucosal Immunoglobulin A Response of Intranasal Adenoviral Vector Human Immunodeficiency Virus Vaccine and Localization in the Central Nervous System

  2003cited by this paper
• On the Use of DNA Vaccines for the Prophylaxis of Mycobacterial Diseases

  2003influential reference
• CD40 ligand (CD154) improves the durability of respiratory syncytial virus DNA vaccination in BALB/c mice.

  2003cited by this paper
• Dendritic-cell control of pathogen-driven T-cell polarization

  2003cited by this paper
• Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus.

  2003cited by this paper

• Advancement in Nanoparticle-Based Drug Delivery for Pulmonary Fibrosis: Current Insights and Future Prospects

  2025cites this paper
• Cyclodextrin-Based Nanotransporters as a Versatile Tool to Manage Oxidative Stress-Induced Lung Diseases

  2025cites this paper
• Cellular vesicles-based “all-in-one” vaccine platform triggers mucosal immunity against respiratory viruses

  2024cites this paper
• An Updated Review on Nanoemulsion: Factory for Food and Drug Delivery.

  2024cites this paper
• Nebulized inhalation of LPAE-HDAC10 inhibits acetylation-mediated ROS/NF-κB pathway for silicosis treatment.

  2023cites this paper
• Repurposing mucosal delivery devices for live attenuated tuberculosis vaccines

  2023cites this paper
• Aerosol Pulmonary Immune Engineering.

  2023cites this paper
• Polymeric Nanoparticles for Inhaled Vaccines

  2022cites this paper
• State-of-the-Art Review of The Application and Development of Various Methods of Aerosol Therapy.

  2021cites this paper
• Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines

  2021cites this paper
• Nanomedicine in pulmonary delivery

  2021cites this paper
• Alternative vaccine delivery methods

  2020cites this paper
• Inhalable polymeric dry powders for antituberculosis drug delivery

  2020cites this paper
• gB co‐immunization with GP96 enhances pulmonary‐resident CD8 T cells and exerts a long‐term defence against MCMV pneumonitis

  2020cites this paper
• Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis

  2019cites this paper
• Eimeria tenella Elongation Factor-1α (EF-1α) Coadministered with Chicken IL-7 (chIL-7) DNA Vaccine Emulsified in Montanide Gel 01 Adjuvant Enhanced the Immune Response to E. acervulina Infection in Broiler Chickens

  2019cites this paper
• Immunogenicity and protective efficacy of a new Leishmania hypothetical protein applied as a DNA vaccine or in a recombinant form against Leishmania infantum infection.

  2019cites this paper
• Aerosol Therapy Development and Methods of Increasing Nebulization Effectiveness

  2018cites this paper
• Evaluation of a Leishmania hypothetical protein administered as DNA vaccine or recombinant protein against Leishmania infantum infection and its immunogenicity in humans.

  2018cites this paper
• Inhaled gene delivery: a formulation and delivery approach

  2017cites this paper
• Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles

  2017cites this paper
• Nanomedicines against Infectious Diseases

  2016cites this paper
• Molecular mechanisms for enhanced DNA vaccine immunogenicity

  2016cites this paper
• Dry powder inhalable formulations for anti-tubercular therapy.

  2016cites this paper
• Emerging Nanotechnology Approaches for Pulmonary Delivery of Vaccines

  2014cites this paper
• Using Plasmids as DNA Vaccines for Infectious Diseases

  2014cites this paper
• Approaches to tuberculosis mucosal vaccine development using nanoparticles and microparticles: a review.

  2014cites this paper
• Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives

  2014cites this paper
• Development of probiotic‐based immunoparticles for pulmonary immunization against Hepatitis B

  2014cites this paper
• Inhalable VaccInes for Tb

  2014cites this paper
• Fate of TLR-1/TLR-2 agonist functionalised pDNA nanoparticles upon deposition at the human bronchial epithelium in vitro

  2013cites this paper
• Inhaled Vaccines for the Prevention of Tuberculosis

  2013cites this paper
• Chitosan‐Based Systems for Mucosal Delivery of Biopharmaceuticals

  2012cites this paper
• A potential nanomedicine consisting of heparin-loaded polysaccharide nanocarriers for the treatment of asthma.

  2012cites this paper
• Optimization of a spray drying process to prepare dry powder microparticles containing plasmid nanocomplex.

  2012cites this paper
• Inhaled Vaccines for the Prevention of Tuberculosis

  2012cites this paper
• Chitosan-Based Particulate Systems for Non-Invasive Vaccine Delivery

  2011cites this paper
• Optimization and characterization of dry powder of fanhuncaoin for inhalation based on selection of excipients.

  2011cites this paper
• Pulmonary Delivery of Plasmid DNA for Disease Prevention and Therapy

  2011cites this paper
• New developments in dry powder pulmonary vaccine delivery.

  2011cites this paper
• In vitro reporter gene transfection via plasmid DNA delivered by metered dose inhaler.

  2010cites this paper
• Comparison of immune response in sheep immunized with DNA vaccine encoding Toxoplasma gondii GRA7 antigen in different adjuvant formulations.

  2010cites this paper
• Adjuvants in tuberculosis vaccine development.

  2010cites this paper
• Pulmonary drug delivery: medicines for inhalation.

  2010cites this paper
• Enhanced in vivo gene expression mediated by listeriolysin O incorporated anionic LPDII: Its utility in cytotoxic T lymphocyte-inducing DNA vaccine.

  2010cites this paper
• Characterisation of plasmid DNA complexes for application in genetic immunization

  2010cites this paper
• Particle Size Influences the Immune Response Produced by Hepatitis B Vaccine Formulated in Inhalable Particles

  2010influential citation
• Designing HIV gp120 peptide vaccines: rhetoric or reality for neuro-AIDs.

  2009cites this paper
• Preclinical models for pulmonary drug delivery

  2009cites this paper
• Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice.

  2009cites this paper
• Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses.

  2009cites this paper
• Opportunities and challenges in vaccine delivery.

  2009cites this paper
• Discovery of dormancy associated antigens of Mycobacterium tuberculosis : novel targets for the development of post-exposure or therapeutic tuberculosis vaccines

  2009cites this paper
• Stimulation of human macrophages (THP-1) using Toll-like receptor-2 (TLR-2) agonist decorated nanocarriers

  2009cites this paper
• Biodegradable polymeric nanocarriers for pulmonary drug delivery.

  2008cites this paper
• Biodegradable polymeric nanocarriers for pulmonary drug delivery

  2008cites this paper
• Feasibility study of inhaled hepatitis B vaccine formulated with tetradecylmaltoside.

  2008cites this paper
• Proinflammatory Signals in the Lung DNA Tuberculosis Vaccination: Role of Immunity by Single Intramuscular Plasmid Antigens Restores Protective Mucosal Airway Delivery of Soluble Mycobacterial

  2008cites this paper
• Solvent-solute interactions in hydrofluoroalkane propellants.

  2008cites this paper
• In Vitro Models of the Tracheo-Bronchial Epithelium

  2008cites this paper
• Biodegradablepolymeric nanocarriersforpulmonary drugdelivery

  2008cites this paper
• Core–shell Particles for the Dispersion of Small Polar Drugs and Biomolecules in Hydrofluoroalkane Propellants

  2008cites this paper
• Extracellular barriers in respiratory gene therapy☆

  2008cites this paper
• Immunization by a bacterial aerosol

  2008cites this paper
• Nanoparticle clearance from the airways : development and testing of a new in vitro model to investigate mucociliary clearance of aerosol particles

  2008cites this paper
• Airway Delivery of Soluble Mycobacterial Antigens Restores Protective Mucosal Immunity by Single Intramuscular Plasmid DNA Tuberculosis Vaccination: Role of Proinflammatory Signals in the Lung1

  2008cites this paper
• Formulation of stable protein powders by supercritical fluid drying

  2007cites this paper
• Design of hydrofluoroalkane-philic moieties for novel propellant-based inhalation formulations: A combined computational and experimental approach

  2007cites this paper
• Understanding solvation in hydrofluoroalkanes: ab initio calculations and chemical force microscopy.

  2007cites this paper
• Epidermal Langerhans Cells Are Dispensable for Humoral and Cell-Mediated Immunity Elicited by Gene Gun Immunization1

  2007cites this paper
• Design of nanoparticle-based dry powder pulmonary vaccines

  2007cites this paper
• Elicited by Gene Gun Immunization for Humoral and Cell-Mediated Immunity Epidermal Langerhans Cells Are Dispensable

  2007cites this paper
• DNA vaccines: are they still just a powerful tool for the future?

  2007influential citation
• Pulmonary delivery of nucleic acids

  2007cites this paper
• Pulmonary vaccine delivery

  2007cites this paper
• Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles.

  2006cites this paper
• Nanotechnology: Intelligent Design to Treat Complex Disease

  2006cites this paper
• Comparative immunogenicity of M. hyopneumoniae NrdF encoded in different expression systems delivered orally via attenuated S. typhimurium aroA in mice.

  2006cites this paper
• The performance of nanocarriers for transmucosal drug delivery

  2006cites this paper
• The present state and future of dry powder inhalation system

  2006cites this paper
• Bioregulators as prototypic nontraditional threat agents.

  2006cites this paper